EP0557129B1 - Product for assisting a smoker in giving-up the habit - Google Patents
Product for assisting a smoker in giving-up the habit Download PDFInfo
- Publication number
- EP0557129B1 EP0557129B1 EP93301249A EP93301249A EP0557129B1 EP 0557129 B1 EP0557129 B1 EP 0557129B1 EP 93301249 A EP93301249 A EP 93301249A EP 93301249 A EP93301249 A EP 93301249A EP 0557129 B1 EP0557129 B1 EP 0557129B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- nicotine
- containers
- percentage
- pharmaceutically acceptable
- volume
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims abstract description 57
- 229960002715 nicotine Drugs 0.000 claims abstract description 57
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims abstract description 57
- 239000003937 drug carrier Substances 0.000 claims abstract description 10
- 239000000443 aerosol Substances 0.000 claims abstract description 8
- 239000007788 liquid Substances 0.000 claims abstract description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 abstract description 12
- 230000000391 smoking effect Effects 0.000 abstract description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 6
- 235000011187 glycerol Nutrition 0.000 abstract description 6
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 abstract description 4
- 239000000126 substance Substances 0.000 abstract description 4
- 230000007423 decrease Effects 0.000 abstract description 3
- 235000019504 cigarettes Nutrition 0.000 description 11
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 239000000779 smoke Substances 0.000 description 3
- 235000019788 craving Nutrition 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000007967 peppermint flavor Substances 0.000 description 2
- 206010012335 Dependence Diseases 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 206010057852 Nicotine dependence Diseases 0.000 description 1
- 208000025569 Tobacco Use disease Diseases 0.000 description 1
- 239000008376 breath freshener Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 230000000881 depressing effect Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000011269 tar Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
- A24F—SMOKERS' REQUISITES; MATCH BOXES; SIMULATED SMOKING DEVICES
- A24F42/00—Simulated smoking devices other than electrically operated; Component parts thereof; Manufacture or testing thereof
- A24F42/20—Devices without heating means
Definitions
- THIS INVENTION relates to a product for assisting a smoker in giving-up the smoking habit.
- Cigarette smoke contains a large number of very complex substances the most important of which is nicotine, this being the substance to which cigarette smokers develop an addiction.
- nicotine this being the substance to which cigarette smokers develop an addiction.
- withdrawal symptoms and a craving for a cigarette occur which result from the body's need for nicotine.
- the person attempting to break the smoking habit should be given decreasing doses of nicotine. This enables the nicotine level in the body to be reduced over a period of time which results in the withdrawal symptoms being less severe.
- Chewing gum with nicotine in it and tablets containing nicotine have been marketed. More recently pads which are applied to the skin have become available. Pads of various sizes are provided, the pads containing nicotine.
- the object of the present invention is to provide an efficacious product for assisting a person in giving-up the smoking habit.
- a plurality of containers each of which, apart from one, contains nicotine in liquid form dispersed in at least one pharmaceutically acceptable carrier, the percentage of nicotine by volume in each container being different to the percentage of nicotine in each other container, and said one container having therein said pharmaceutically acceptable carrier but no nicotine.
- the nicotine should not constitute more than 2% by volume of the contents of the container.
- the containers can contain about 1,5%, about 1,0%, about 0,5% and 0,0% by volume nicotine.
- the percentage of nicotine in the three containers can be 1,45%, 0,97% and 0,48%. Experimentation has shown that four containers containing these volumes of nicotine provides a suitable treatment for a person smoking about 30 cigarettes per day.
- the containers are preferably pump operated aerosol cans so that depressing the plunger once dispenses a predetermined volume of liquid from the can. This minimises the risk that the person may receive too heavy a dose which can occur if an aerosol can of the type which contains a propellant under pressure is used.
- Suitable pharmaceutically acceptable liquid carriers are alcohol, glycerine, saccharine and a flavouring such as peppermint.
- the alcohol can occupy the greatest volume eg from 75% to 85%, the volume of alcohol increasing as the percentage of nicotine decreases.
- the peppermint flavour can be about 4% by volume and the saccharine a trace eg 0.1% by volume.
- the following table sets out the ingredients of four cans each having a volume of 20ml and the nicotine content of which ranges from 1.45% to 0% and which is suitable for the treatment, over a period of about 1 month, of a person who at the beginning of treatment is smoking about 30 cigarettes per day.
- One depression of the plunger is sufficient to dispense a suitable amount of liquid in atomized form.
- the first can is used each time that the person feels like smoking a cigarette until it is exhausted.
- the second aerosol can is then used in the same way and it will be understood that the person is, immediately the second can is brought into use, receiving a smaller dose of nicotine per depression of the pump than was being received during use of the first can.
- the amount provided has been decreased.
- the third can is brought into use and subsequently the fourth can which has therein no nicotine whatsoever.
- the nicotine level of the patient is decreased gradually and the effects of a sudden reduction in the nicotine level in the body are avoided.
- the nicotine be in a pump actuated aerosol can
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Treatment And Processing Of Natural Fur Or Leather (AREA)
- General Preparation And Processing Of Foods (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
- THIS INVENTION relates to a product for assisting a smoker in giving-up the smoking habit.
- Cigarette smoke contains a large number of very complex substances the most important of which is nicotine, this being the substance to which cigarette smokers develop an addiction. Upon a cigarette smoker ceasing to smoke, withdrawal symptoms and a craving for a cigarette occur which result from the body's need for nicotine. To alleviate the effect of these withdrawal symptoms and the craving for a cigarette it has been proposed that the person attempting to break the smoking habit should be given decreasing doses of nicotine. This enables the nicotine level in the body to be reduced over a period of time which results in the withdrawal symptoms being less severe. Chewing gum with nicotine in it and tablets containing nicotine have been marketed. More recently pads which are applied to the skin have become available. Pads of various sizes are provided, the pads containing nicotine. The nicotine is absorbed steadily through the skin. The concept is that a large pad is used initially when the person attempting to give-up the smoking habit requires a high level of nicotine in his or her body to prevent withdrawal symptoms. Pads of progressively decreasing size are used as the body becomes less dependant on nicotine. In this regard reference is made to US patent 4920989 which discloses such pads.
- The concept of inhaling nicotine from an aerosol device is also known and reference can be made to US Patents 4813437 and 4945929. The purpose of such devices is to provide the user with the nicotine that his or her body requires without smoke, tars and other harmful substances found in cigarettes simultaneously being inhaled. Thus the known aerosol products are substitutes for cigarettes and do not assist a smoker in ridding himself or herself of nicotine addiction. Nicotine addition is the main reason why giving up the smoking habit is so difficult.
- The object of the present invention is to provide an efficacious product for assisting a person in giving-up the smoking habit.
- According to the present invention there is provided a plurality of containers each of which, apart from one, contains nicotine in liquid form dispersed in at least one pharmaceutically acceptable carrier, the percentage of nicotine by volume in each container being different to the percentage of nicotine in each other container, and said one container having therein said pharmaceutically acceptable carrier but no nicotine.
- The nicotine should not constitute more than 2% by volume of the contents of the container.
- There should be at least three containers, two containers having nicotine therein with the percentage of nicotine in one of these containers being greater than the percentage of nicotine in the other of these containers, the third container containing said pharmaceutically acceptable carrier but no nicotine.
- It is preferred that there be four containers, three containers having nicotine therein with the percentage of nicotine in each of these containers being different to the percentage in each of the others of these three containers, the fourth container having therein at least one pharmaceutically acceptable carrier but no nicotine.
- The containers can contain about 1,5%, about 1,0%, about 0,5% and 0,0% by volume nicotine. By way of example, the percentage of nicotine in the three containers can be 1,45%, 0,97% and 0,48%. Experimentation has shown that four containers containing these volumes of nicotine provides a suitable treatment for a person smoking about 30 cigarettes per day.
- The containers are preferably pump operated aerosol cans so that depressing the plunger once dispenses a predetermined volume of liquid from the can. This minimises the risk that the person may receive too heavy a dose which can occur if an aerosol can of the type which contains a propellant under pressure is used.
- Suitable pharmaceutically acceptable liquid carriers are alcohol, glycerine, saccharine and a flavouring such as peppermint. The alcohol can occupy the greatest volume eg from 75% to 85%, the volume of alcohol increasing as the percentage of nicotine decreases. There can be between 10- and 20% glycerine, the volume of glycerine increasing as the volume of nicotine decreases. The peppermint flavour can be about 4% by volume and the saccharine a trace eg 0.1% by volume.
- The following table sets out the ingredients of four cans each having a volume of 20ml and the nicotine content of which ranges from 1.45% to 0% and which is suitable for the treatment, over a period of about 1 month, of a person who at the beginning of treatment is smoking about 30 cigarettes per day.
Can 1 Can 2 Can 3 Can 4 Nicotine 1.45 0.97 0.48 0.00 Alcohol 79.71 80.10 80.49 80.88 Saccharine 0.12 0.12 0.12 0.12 Glycerine 14.78 14.85 14.93 15.00 Peppermint Flavour 3.94 3.96 3.98 4.00 All figures are percentages by volume. - The person wishing to give up smoking, upon feeling the need for a cigarette, takes the can which contains most nicotine and, in the way that breath fresheners are used, sprays into his or her mouth. One depression of the plunger is sufficient to dispense a suitable amount of liquid in atomized form. The first can is used each time that the person feels like smoking a cigarette until it is exhausted. The second aerosol can is then used in the same way and it will be understood that the person is, immediately the second can is brought into use, receiving a smaller dose of nicotine per depression of the pump than was being received during use of the first can. Thus while nicotine is still being provided, the amount provided has been decreased. Once the second can has been depleted the third can is brought into use and subsequently the fourth can which has therein no nicotine whatsoever. Thus the nicotine level of the patient is decreased gradually and the effects of a sudden reduction in the nicotine level in the body are avoided.
- Whilst it is preferred that the nicotine be in a pump actuated aerosol can, it is possible for it to be in a bottle for application by medicine measure or by dropper or in a deformable squeeze bottle with a nozzle, such bottles currently being used, for example, to apply nasal sprays.
Claims (6)
- A plurality of containers each of which, apart from one, contains nicotine in liquid form dispersed in at least one pharmaceutically acceptable carrier, the percentage of nicotine by volume in each container being different to the percentage of nicotine in each other container, and said one container having therein said pharmaceutically acceptable carrier but no nicotine.
- A plurality of containers according to claim 1, the number of containers being three, two containers having nicotine therein with the percentage of nicotine in one of these containers being greater than the percentage of nicotine in the other of these containers, the third container containing said pharmaceutically acceptable carrier but no nicotine.
- A plurality of containers according to claim 1, the number of containers being four, three containers having nicotine therein with the percentage of nicotine in each of these containers being different to the percentage in each of the others of these three containers, the fourth container having therein at least one pharmaceutically acceptable carrier but no nicotine.
- A plurality of containers according to claim 3, wherein the percentage of nicotine in said three containers is respectively about 1,5%, about 1% and about 0,5%.
- A plurality of containers according to Claim 3, wherein the percentage of nicotine in said three containers is respectively 1,45%, 0,97% and 0,48%.
- A plurality of containers according to any one of Claims 1 to 5 and which are pump operated aerosol containers.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ZA921245 | 1992-02-20 | ||
| ZA921245 | 1992-02-20 | ||
| ZA926655A ZA926655B (en) | 1992-02-20 | 1992-09-02 | Product for assiting a smoker in giving-up the habit. |
| ZA926655 | 1992-09-02 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP0557129A1 EP0557129A1 (en) | 1993-08-25 |
| EP0557129B1 true EP0557129B1 (en) | 1996-11-06 |
Family
ID=27142154
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP93301249A Expired - Lifetime EP0557129B1 (en) | 1992-02-20 | 1993-02-19 | Product for assisting a smoker in giving-up the habit |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP0557129B1 (en) |
| JP (1) | JP3661131B2 (en) |
| AT (1) | ATE144884T1 (en) |
| DE (1) | DE69305759T2 (en) |
| DK (1) | DK0557129T3 (en) |
| ES (1) | ES2097443T3 (en) |
| GR (1) | GR3022506T3 (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7900637B2 (en) | 2001-06-25 | 2011-03-08 | Niconovum Ab | Device and method for the administration of a substance |
| US8236285B2 (en) | 1997-10-01 | 2012-08-07 | Novadel Pharma Inc. | Buccal, polar and non-polar spray containing zolpidem |
| US8741348B2 (en) | 2002-12-20 | 2014-06-03 | Niconovum Ab | Physically and chemically stable nicotine-containing particulate material |
| US9402809B2 (en) | 2006-03-16 | 2016-08-02 | Niconovum Usa, Inc. | Snuff composition |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2190697A (en) * | 1996-04-12 | 1997-11-07 | Flemington Pharmaceutical Corporation | Buccal polar spray or capsule |
| US20030185761A1 (en) | 1997-10-01 | 2003-10-02 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating pain |
| US20030077227A1 (en) | 1997-10-01 | 2003-04-24 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system |
| US20040136914A1 (en) | 1997-10-01 | 2004-07-15 | Dugger Harry A. | Buccal, polar and non-polar spray containing ondansetron |
| EP2042161A1 (en) | 1997-10-01 | 2009-04-01 | Novadel Pharma Inc. | Propellant-free spray composition comprising anti-emetic agent |
| US8256433B2 (en) | 1999-07-16 | 2012-09-04 | Aradigm Corporation | Systems and methods for effecting cessation of tobacco use |
| JP4999245B2 (en) * | 1999-07-16 | 2012-08-15 | アラディグム コーポレイション | System for achieving quit smoking |
| JP5577021B2 (en) | 2005-02-17 | 2014-08-20 | アボット・ラボラトリーズ | Transmucosal administration of pharmaceutical compositions for treating and preventing disorders in animals |
| WO2008069972A2 (en) * | 2006-12-01 | 2008-06-12 | Aradigm Corporation | Systems for effecting cessation of tobacco use |
| GB201213870D0 (en) * | 2012-08-03 | 2012-09-19 | British American Tobacco Co | Tobacco extract, preparation thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4284089A (en) * | 1978-10-02 | 1981-08-18 | Ray Jon P | Simulated smoking device |
| US4813437A (en) | 1984-01-09 | 1989-03-21 | Ray J Philip | Nicotine dispensing device and method for the manufacture thereof |
| US4920989A (en) | 1985-04-25 | 1990-05-01 | Regents Of The University Of California | Method and apparatus for aiding in the reduction of incidence of tobacco smoking |
| GB8614805D0 (en) | 1986-06-18 | 1986-07-23 | British American Tobacco Co | Aerosol device |
| IL83826A (en) * | 1987-09-08 | 1991-03-10 | Inventor S Funding Corp Ltd | Plastic mouthpiece for simulated smoking |
| US5167242A (en) * | 1990-06-08 | 1992-12-01 | Kabi Pharmacia Aktiebolaq | Nicotine-impermeable container and method of fabricating the same |
-
1993
- 1993-02-19 JP JP03093793A patent/JP3661131B2/en not_active Expired - Fee Related
- 1993-02-19 DK DK93301249.4T patent/DK0557129T3/en active
- 1993-02-19 ES ES93301249T patent/ES2097443T3/en not_active Expired - Lifetime
- 1993-02-19 EP EP93301249A patent/EP0557129B1/en not_active Expired - Lifetime
- 1993-02-19 DE DE69305759T patent/DE69305759T2/en not_active Expired - Lifetime
- 1993-02-19 AT AT93301249T patent/ATE144884T1/en active
-
1997
- 1997-02-06 GR GR970400201T patent/GR3022506T3/en unknown
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8236285B2 (en) | 1997-10-01 | 2012-08-07 | Novadel Pharma Inc. | Buccal, polar and non-polar spray containing zolpidem |
| US7900637B2 (en) | 2001-06-25 | 2011-03-08 | Niconovum Ab | Device and method for the administration of a substance |
| US8741348B2 (en) | 2002-12-20 | 2014-06-03 | Niconovum Ab | Physically and chemically stable nicotine-containing particulate material |
| US9402809B2 (en) | 2006-03-16 | 2016-08-02 | Niconovum Usa, Inc. | Snuff composition |
Also Published As
| Publication number | Publication date |
|---|---|
| DE69305759D1 (en) | 1996-12-12 |
| GR3022506T3 (en) | 1997-05-31 |
| JP3661131B2 (en) | 2005-06-15 |
| ATE144884T1 (en) | 1996-11-15 |
| ES2097443T3 (en) | 1997-04-01 |
| DK0557129T3 (en) | 1997-04-14 |
| EP0557129A1 (en) | 1993-08-25 |
| JPH06315367A (en) | 1994-11-15 |
| DE69305759T2 (en) | 1997-06-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6024097A (en) | Product for assisting a smoker in giving up the habit | |
| US5456677A (en) | Method for oral spray administration of caffeine | |
| EP0557129B1 (en) | Product for assisting a smoker in giving-up the habit | |
| US5893371A (en) | Non-nicotine smoking cessation aid | |
| CA2127253C (en) | Composition to help stop smoking | |
| US5810018A (en) | Method, composition and apparatus for reducing the incidence of cigarette smoking | |
| Sutherland et al. | Nasal nicotine spray: a rapid nicotine delivery system | |
| CA2447510A1 (en) | Fluorocarbon aerosol medicaments | |
| US20060162732A1 (en) | Method for making a nicotine toothpick | |
| TW200416051A (en) | Inhalation device and method for delivering variable amounts of different components | |
| JP2004512907A (en) | Device and method for smoking cessation | |
| HUP0002645A2 (en) | Phospholipid containing pharmaceutical composition for treating sleep apnea and apparatus for enabling the administration thereof | |
| RU94040361A (en) | AEROSOL PHARMACEUTICAL COMPOSITION, SPRAYER FOR DELIVERY OF THE COMPOSITION, DOSAGE INHALATOR, METHOD FOR TREATING RESPIRATORY DISEASES, METHOD FOR PRODUCING THE COMPOSITION | |
| JPS63503303A (en) | Pharmaceutical preparations and their manufacturing methods | |
| MXPA02008778A (en) | Pharmaceutical compositions. | |
| KR101760972B1 (en) | Inhibition of undesired sensory effects by the compound camphor | |
| US5744124A (en) | Nitroglycerin-containing hydrophilic aqueous pumpable spray composition | |
| TW200427417A (en) | A container comprising nicotine and the use and manufacture thereof | |
| US20210251277A1 (en) | Synthetic Fiber Oral Flavored Product | |
| GB2133691A (en) | Smoking substitutes for nasal administration | |
| EP3967298A1 (en) | Aerosol composition for oral use | |
| US3156614A (en) | Medicinal compositions and method for relieving cough | |
| EP0450253B1 (en) | Means for breaking the habitual use of tobacco | |
| WO2001062264A3 (en) | Halotherapy method by inhalation of sodium chloride | |
| WO1997011739A1 (en) | Method and apparatus for oral spray administration of caffeine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT CH DE DK ES FR GB GR IT LI NL PT SE |
|
| 17P | Request for examination filed |
Effective date: 19940224 |
|
| 17Q | First examination report despatched |
Effective date: 19951004 |
|
| GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
| GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
| GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
| AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT CH DE DK ES FR GB GR IT LI NL PT SE |
|
| REF | Corresponds to: |
Ref document number: 144884 Country of ref document: AT Date of ref document: 19961115 Kind code of ref document: T |
|
| REF | Corresponds to: |
Ref document number: 69305759 Country of ref document: DE Date of ref document: 19961212 |
|
| ITF | It: translation for a ep patent filed | ||
| ET | Fr: translation filed | ||
| REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2097443 Country of ref document: ES Kind code of ref document: T3 |
|
| ET | Fr: translation filed |
Free format text: CORRECTIONS |
|
| REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 |
|
| REG | Reference to a national code |
Ref country code: GR Ref legal event code: FG4A Free format text: 3022506 |
|
| PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
| 26N | No opposition filed | ||
| REG | Reference to a national code |
Ref country code: PT Ref legal event code: PC4A Free format text: J MOM TRUST VG Effective date: 19991108 |
|
| REG | Reference to a national code |
Ref country code: ES Ref legal event code: PC2A |
|
| REG | Reference to a national code |
Ref country code: FR Ref legal event code: TP |
|
| NLS | Nl: assignments of ep-patents |
Owner name: J MOM TRUST |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: PUE Owner name: VON WIELLIGH, JOHANNES LOUW KOTZE TRANSFER- J MOM Ref country code: CH Ref legal event code: NV Representative=s name: PATENTANWALTSBUERO EDER AG |
|
| REG | Reference to a national code |
Ref country code: GB Ref legal event code: 732E |
|
| REG | Reference to a national code |
Ref country code: GB Ref legal event code: IF02 |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: PUE Owner name: J MOM TRUST TRANSFER- ASPEN PHARMACARE EUROPE LTD |
|
| REG | Reference to a national code |
Ref country code: GB Ref legal event code: 732E |
|
| REG | Reference to a national code |
Ref country code: PT Ref legal event code: PC4A Free format text: ASPEN PHARMACARE EUROPE LTD. GB Effective date: 20020816 |
|
| REG | Reference to a national code |
Ref country code: FR Ref legal event code: TP |
|
| REG | Reference to a national code |
Ref country code: ES Ref legal event code: PC2A |
|
| NLS | Nl: assignments of ep-patents |
Owner name: ASPEN PHARMACARE EUROPE LTD |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DK Payment date: 20110210 Year of fee payment: 19 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: PT Payment date: 20110216 Year of fee payment: 19 Ref country code: SE Payment date: 20110211 Year of fee payment: 19 Ref country code: DE Payment date: 20110216 Year of fee payment: 19 Ref country code: AT Payment date: 20110210 Year of fee payment: 19 Ref country code: CH Payment date: 20110214 Year of fee payment: 19 Ref country code: IT Payment date: 20110219 Year of fee payment: 19 Ref country code: NL Payment date: 20110216 Year of fee payment: 19 Ref country code: FR Payment date: 20110218 Year of fee payment: 19 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GR Payment date: 20110217 Year of fee payment: 19 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20110216 Year of fee payment: 19 Ref country code: ES Payment date: 20110315 Year of fee payment: 19 |
|
| REG | Reference to a national code |
Ref country code: PT Ref legal event code: MM4A Free format text: LAPSE DUE TO NON-PAYMENT OF FEES Effective date: 20120820 |
|
| REG | Reference to a national code |
Ref country code: NL Ref legal event code: V1 Effective date: 20120901 |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
| GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20120219 |
|
| REG | Reference to a national code |
Ref country code: GR Ref legal event code: ML Ref document number: 970400201 Country of ref document: GR Effective date: 20120905 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120229 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120229 Ref country code: SE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120220 |
|
| REG | Reference to a national code |
Ref country code: DK Ref legal event code: EBP |
|
| REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST Effective date: 20121031 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120905 Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120219 Ref country code: PT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120820 |
|
| REG | Reference to a national code |
Ref country code: AT Ref legal event code: MM01 Ref document number: 144884 Country of ref document: AT Kind code of ref document: T Effective date: 20120219 |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 69305759 Country of ref document: DE Effective date: 20120901 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120901 Ref country code: AT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120219 Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120229 Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120219 |
|
| REG | Reference to a national code |
Ref country code: PT Ref legal event code: MM4A Free format text: MAXIMUM VALIDITY LIMIT REACHED Effective date: 20130219 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20130227 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120901 |
|
| REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20130708 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120220 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120229 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20120219 |